

**Supplementary Table 1.** Demographics, symptomatology, and other key features of healthy convalescent individuals and patients with long COVID.

<b>Characteristic</b>	<b>Controls (n = 79)</b>	<b>Long COVID (n = 166)</b>
<b>Age (years), median (range)</b>	45 (21–82)	47 (20–83)
<b>Female</b>	62 (78.5%)	127 (76.5%)
<b>Ethnicity/race</b>		
White	67 (84.8%)	146 (88.0%)
Black	0 (0.0%)	3 (1.8%)
Asian	8 (10.2%)	8 (4.8%)
Mixed ethnicity	2 (2.5%)	2 (1.2%)
Other	2 (2.5%)	7 (4.2%)
<b>Body mass index &gt;30kg/m<sup>2</sup></b>	26/75 (34.6%)	79/162 (48.8%)
<b>Coexisting conditions</b>		
Yes	14 (17.7%)	55 (33.1%)
No	65 (82.3%)	111 (66.9%)
<b>Employment status</b>		
<i>Pre-COVID</i>		
Employed	53 (91.4%)	139 (89.1%)
Employed, altered duties	0 (0.0%)	0 (0.0%)
Employed, sick leave	0 (0.0%)	0 (0.0%)
Unemployed	0 (0.0%)	4 (2.6%)
Retired	2 (3.4%)	11 (7.0%)
Student	3 (5.2%)	2 (1.3%)
<i>Post-COVID</i>		
Employed	54 (93.2%)	68 (43.6%)
Employed, altered duties	0 (0.0%)	28 (17.9%)
Employed, sick leave	0 (0.0%)	33 (21.2%)
Unemployed	0 (0.0%)	11 (7.1%)
Retired	2 (3.4%)	13 (8.3%)
Student	2 (3.4%)	3 (1.9%)
<b>Date of infection with SARS-CoV-2</b>		
March 2020 to August 2020	14 (17.7%)	34 (20.5%)
September 2020 to June 2021	23 (29.1%)	57 (34.3%)
July 2021 to October 2022	42 (53.2%)	75 (45.2%)
<b>COVID vaccination status, median (IQR)</b>		
Number of vaccinations before infection	3 (0–3)	2 (0–2)
Total number of vaccinations	3 (3–3)	3 (3–3)
<b>Symptoms<sup>1</sup></b>		
Breathlessness	0 (0–0)	4 (2–6)
Fatigue	0 (0–2)	6 (4–8)
Musculoskeletal	0 (0–0)	3 (0–6)
Pain	0 (0–0)	4 (2–6)
Neuropsychiatric	0 (0–0)	3 (1–5)
<b>Ability to maintain self-care</b>	0 (0–0)	0 (0–3)
<b>Ability to maintain daily tasks</b>	0 (0–0)	6 (3–8)
<b>Overall general health<sup>2</sup></b>	0 (0 to –1)	–4 (–2 to –6)

<sup>1</sup>Difference in numeric rating scale score (0 = no symptom, 10 = worst possible symptom) before versus after COVID-19 (median ± IQR). <sup>2</sup>Difference in numeric rating scale score (0 = worst possible, 10 = best possible) before versus after COVID-19 (median ± IQR).

**Supplementary Table 2.** Summary of optimized in-house ELISAs.

<b>Assay</b>	<b>Capture antibody</b>	<b>Detection antibody</b>	<b>Detection range</b>	<b>Dilution factor</b>
<i>Activation products</i>				
Ba	Anti-Ba (clone D22/3, Hycult)	Anti-FB–biotin (clone P21/15, Hycult)	8.5–550 ng/ml	1:4
iC3b	Anti-iC3b (clone 9)	Anti-C3c–HRP (mAb bH6, Hycult)	23–1500 ng/ml	1:40
TCC	Anti-TCC (clone aE11, Hycult)	Anti-C8–biotin (mAb E2)	39–2500 ng/ml	1:40
<i>Components</i>				
C1q	Anti-C1q (clone 9H10)	Anti-C1q (rabbit polyclonal)	23–1500 ng/ml	1:16,000
C4	Anti-C4 (rabbit polyclonal)	Anti-C4–HRP (rabbit polyclonal)	15–1000 ng/ml	1:4000
C3	Anti-C3/C3a (clone 2898, Hycult)	Anti-C3d–HRP (clone 3, Hycult)	31–2000 ng/ml	1:2000
FB	Anti-FB (clone JC1)	Anti-FB (goat polyclonal, CompTech)	15–1000 ng/ml	1:3000
C5	Anti-C5 (clone 10B6)	Anti-C5 (clone 4G2)	39–2500 ng/ml	1:2000
C9	Anti-C9 (clone B7)	Anti-C9–biotin (rabbit polyclonal)	3–200 ng/ml	1:4000
<i>Regulators</i>				
C1INH	Anti-C1INH (rabbit polyclonal)	Anti-C1INH–HRP (rabbit polyclonal)	1–125 ng/ml	1:4000
FH	Anti-FH (clone OX24)	Anti-FH–HRP (clone 35H9)	15–1000 ng/ml	1:4000
FHR125	Anti-FHR125 (clone MBI125)	Anti-FH (clone 35H9)	156–10,000 ng/ml	1:100
FHR4	Anti-FHR4 (clone 4E9)	Anti-FHR4–HRP (clone 150)	15–1000 ng/ml	1:100
sCR1	Anti-sCR1 (rabbit polyclonal)	Anti-sCR1–HRP (mAb MBI35)	0.4–25 ng/ml	1:2
Properdin	Anti-properdin (clone 9.3.4, Hycult)	Anti-properdin–HRP (clone 2.9, Hycult)	6–400 ng/ml	1:1600
FD	Anti-FD (rabbit polyclonal)	Anti-FD–HRP (clone D10/4, Hycult)	15–1000 ng/ml	1:100
FI	Anti-FI (clone 7B5)	Anti-FI (rabbit polyclonal)	15–1000 ng/ml	1:500
Clusterin	Anti-clusterin (clone 2D5)	Anti-clusterin–HRP (clone 4C7)	31–2000 ng/ml	1:1000

All antibodies were prepared in-house unless stated otherwise. All standards were prepared in-house, except for iC3b, Ba, properdin, FD, and FB (all from CompTech), and C1INH (Cinryze, Shire Pharma). C1s-C1INH was assayed using a Human C1s/C1-INH Complex ELISA (Hycult Biotech), C5a was assayed using a Human Complement Component C5a Duoset ELISA (R&D Systems), and MASP1-C1INH was assayed using a Human MASP-1/C1-INH Complex ELISA (Hycult Biotech). TCC, terminal complement complex; FB, factor B; C1INH, C1 inhibitor; FH, factor H; FHR125, FH-related proteins 1, 2, and 5; FHR4, FH-related protein 4; sCR1, soluble complement receptor type 1; FD, factor D; FI, factor I; HRP, horseradish peroxidase.

**Supplementary Table 3.** Statistics for comparing the distributions of complement protein concentrations in plasma in healthy convalescent individuals and patients with long COVID.

Protein	Control Median	Control IQR	Long COVID Median	Long COVID IQR	P value
<i>Activation products</i>					
C1s-C1INH $\mu\text{g/ml}$	1.114	0.470	1.191	0.602	<b>0.0237</b>
MASP1-C1INH $\text{ng/ml}$	51.998	37.595	49.706	52.723	0.644
Ba $\mu\text{g/ml}$	0.191	0.149	0.221	0.249	<b>0.00889</b>
iC3b $\mu\text{g/ml}$	11.904	7.132	17.089	13.487	<b>2.29E-08</b>
C5a $\text{ng/ml}$	4.533	3.142	5.275	3.411	0.0855
TCC $\mu\text{g/ml}$	3.426	2.436	5.301	3.103	<b>2.34E-08</b>
<i>Components</i>					
C1q $\mu\text{g/ml}$	117.916	137.751	108.310	121.844	<b>0.023</b>
C4 $\mu\text{g/ml}$	426.654	214.485	468.643	189.476	0.836
C3 $\mu\text{g/ml}$	836.095	191.517	872.514	205.933	<b>0.0408</b>
FB $\mu\text{g/ml}$	245.815	117.479	250.730	137.235	0.637
C5 $\mu\text{g/ml}$	175.114	53.613	191.596	65.589	<b>0.00314</b>
C9 $\mu\text{g/ml}$	83.639	33.869	89.597	36.443	<b>0.0163</b>
<i>Regulators</i>					
C1INH $\mu\text{g/ml}$	96.992	40.394	113.515	45.481	<b>0.000621</b>
FH $\mu\text{g/ml}$	233.574	118.639	250.472	94.885	0.0677
FHR125 $\mu\text{g/ml}$	79.938	82.719	85.551	87.266	0.471
FHR4 $\mu\text{g/ml}$	3.724	1.907	3.573	1.959	0.735
sCR1 $\text{ng/ml}$	6.183	1.956	6.202	2.075	0.327
Properdin $\mu\text{g/ml}$	2.931	0.942	3.425	1.391	<b>7.36E-05</b>
FD $\mu\text{g/ml}$	0.618	0.294	0.844	0.370	<b>2.88E-07</b>
FI $\mu\text{g/ml}$	53.164	15.724	54.093	18.685	0.539
Clusterin $\mu\text{g/ml}$	131.67	25.733	137.644	66.457	0.228

P values were calculated using the Wilcoxon-Mann-Whitney test. Significant differences are highlighted in bold font. C1INH, C1 inhibitor; MASP1, mannose-associated serine protease 1; TCC, terminal complement complex; FB, factor B; FH, factor H; FHR125, FH-related proteins 1, 2, and 5; FHR4, FH-related protein 4; sCR1, soluble complement receptor type 1; FD, factor D; FI, factor I.

**Supplementary Table 4.** Statistics for generalized linear models using unadjusted complement protein concentrations in plasma to predict long COVID.

Protein	AUC	CI	Z	SE	P value
iC3b	0.744	0.617–0.859	2.388	0.228	<b>0.0169</b>
TCC	0.687	0.547–0.814	3.765	0.262	<b>0.000166</b>
Ba	0.679	0.542–0.802	2.065	0.357	<b>0.0389</b>
C1q	0.452	0.312–0.601	–1.342	0.176	0.18
C3	0.667	0.525–0.797	1.105	0.185	0.269
C4	0.536	0.369–0.694	–0.956	0.178	0.339
C5	0.512	0.352–0.671	3.203	0.219	<b>0.00136</b>
C9	0.625	0.47–0.768	2.278	0.193	<b>0.0227</b>
C1INH	0.744	0.614–0.859	1.741	0.184	<b>0.0817</b>
FH	0.65	0.507–0.785	1.15	0.186	0.25
FHR4	0.485	0.337–0.627	–0.509	0.17	0.61
FHR125	0.484	0.341–0.632	0.306	0.185	0.759
FI	0.521	0.368–0.671	1.091	0.167	0.275
Clusterin	0.554	0.422–0.683	1.264	0.201	0.206
FD	0.707	0.566–0.843	2.392	0.254	<b>0.0167</b>
Properdin	0.618	0.467–0.752	3.157	0.314	<b>0.0016</b>
FB	0.528	0.356–0.688	0.526	0.193	0.599
sCR1	0.626	0.487–0.759	–0.604	0.161	0.546
C1s-C1INH	0.567	0.418–0.719	1.567	0.186	0.117
MASP1-C1INH	0.553	0.399–0.699	0.825	0.211	0.409
C5a	0.544	0.391–0.694	1.707	0.384	0.0879

AUC, area under the curve; CI, 95% confidence interval (generated from 2000 bootstrap replicates); Z, Z score; SE, standard error. Significant differences are highlighted in bold font. TCC, terminal complement complex; C1INH, C1 inhibitor; FH, factor H; FHR4, FH-related protein 4; FHR125, FH-related proteins 1, 2, and 5; FI, factor I; FD, factor D; FB, factor B; sCR1, soluble complement receptor type 1; MASP1, mannose-associated serine protease 1.

**Supplementary Table 5.** Statistics for generalized linear models using complement protein concentrations in plasma adjusted for age, gender, and BMI to predict long COVID.

<b>Protein</b>	<b>AUC</b>	<b>CI</b>	<b>Z</b>	<b>SE</b>	<b>P value</b>
iC3b	0.729	0.6–0.848	2.325	0.226	<b>0.0201</b>
TCC	0.689	0.557–0.82	3.669	0.282	<b>0.000244</b>
Ba	0.653	0.52–0.776	2.182	0.336	<b>0.0291</b>
C1q	0.434	0.322–0.613	-1.191	0.174	0.234
C3	0.669	0.52–0.791	0.905	0.183	0.365
C4	0.507	0.364–0.674	-1.203	0.17	0.229
C5	0.509	0.353–0.659	3.052	0.224	<b>0.00228</b>
C9	0.642	0.493–0.781	2.051	0.19	<b>0.0403</b>
C1INH	0.746	0.623–0.866	1.729	0.183	0.0839
FH	0.638	0.485–0.767	1.078	0.177	0.281
FHR4	0.522	0.387–0.674	-0.824	0.172	0.41
FHR125	0.446	0.308–0.6	0.467	0.179	0.64
FI	0.528	0.397–0.679	0.669	0.176	0.504
Clusterin	0.591	0.459–0.713	1.363	0.19	0.173
FD	0.686	0.549–0.816	2.329	0.23	<b>0.0198</b>
Properdin	0.654	0.498–0.785	3.161	0.292	<b>0.00157</b>
FB	0.518	0.35–0.678	0.408	0.177	0.684
sCR1	0.599	0.449–0.732	-0.65	0.169	0.516
C1s-C1INH	0.575	0.431–0.726	1.419	0.182	0.156
MASP1-C1INH	0.555	0.396–0.692	0.835	0.185	0.404
C5a	0.634	0.491–0.762	1.849	0.384	0.0644

AUC, area under the curve; CI, 95% confidence interval (generated from 2000 bootstrap replicates); Z, Z score; SE, standard error. Significant differences are highlighted in bold font. TCC, terminal complement complex; C1INH, C1 inhibitor; FH, factor H; FHR4, FH-related protein 4; FHR125, FH-related proteins 1, 2, and 5; FI, factor I; FD, factor D; FB, factor B; sCR1, soluble complement receptor type 1; MASP1, mannose-associated serine protease 1.

**Supplementary Table 6.** Statistics for stepAIC-informed generalized linear models using complement protein concentrations in plasma adjusted for age and gender to predict long COVID.

<b>Model</b>	<b>AUC</b>	<b>AIC</b>	<b>CI</b>	<b>Z</b>	<b>SE</b>	<b>P value</b>
TCC + Ba + C1q + C4 + C5 + C1INH + FD + properdin	0.825	141.85	0.699–0.912	5.16	0.339	2.46E–07
TCC + Ba + C1q + C4 + C5 + C1INH + FD + properdin + sCR1	0.832	142.62	0.714–0.914	5.196	0.343	2.03E–07
TCC + Ba + C1q + C4 + C5 + C1INH + FH + FD + properdin + sCR1	0.831	143.43	0.713–0.909	5.207	0.352	1.91E–07
TCC+ Ba + C1q + C4 + C5 + C9 + C1INH + FH + FD + properdin + sCR1	0.847	144.45	0.726–0.924	5.163	0.351	2.42E–07

AUC, area under the curve; AIC, Akaike Information Criterion; CI, 95% confidence interval (generated from 2000 bootstrap replicates); Z, Z score; SE, standard error. TCC, terminal complement complex; C1INH, C1 inhibitor; FD, factor D; sCR1, soluble complement receptor type 1; FH, factor H.

**Supplementary Table 7.** Statistics for sequential activation generalized linear models using complement protein concentrations in plasma adjusted for age and gender to predict long COVID.

<b>Proteins</b>	<b>AUC</b>	<b>CI</b>	<b>Z</b>	<b>SE</b>	<b>P value</b>
iC3b	0.729	0.6–0.848	4.796	0.183	1.62E–06
iC3b + TCC	0.73	0.594–0.849	4.965	0.21	6.87E–07
iC3b + TCC + Ba	0.775	0.637–0.884	4.991	0.234	6.02E–07
iC3b + TCC + Ba + C5a	0.785	0.662–0.888	4.921	0.248	8.6E–07
iC3b + TCC + Ba + C5a + C1s-C1INH	0.794	0.669–0.889	4.945	0.254	7.61E–07
iC3b + TCC + Ba + C5a + C1s-C1INH + MASP1-C1INH	0.798	0.674–0.892	4.931	0.257	8.19E–07

AUC, area under the curve; CI, 95% confidence interval (generated from 2000 bootstrap replicates); Z, Z score; SE, standard error. Activators of complement proteins were chosen based on the order of individual AUCs, starting with the highest ranked protein (iC3b). TCC, terminal complement complex; C1INH, C1 inhibitor; MASP1, mannose-associated serine protease 1.

**Supplementary Table 8.** Statistics for main three confounders (age, gender, and BMI) in generalized linear models using complement biomarker concentrations in plasma to predict long COVID.

Model	AUC	CI	Z	SE	P value	CI DeLong	Z DeLong	P value DeLong
Age + gender + BMI	0.491	0.332–0.658	1.077	0.014	0.281	NA	NA	NA
+ iC3b	0.723	0.587–0.846	2.34	0.228	0.0193	-0.0947	-3.31	0.000928
+ TCC	0.708	0.571–0.836	3.647	0.264	0.000265	-0.042	-2.43	0.0151
+ Ba	0.636	0.503–0.756	2.15	0.369	0.0316	-0.0173	-2.23	0.0261
+ C1q	0.477	0.326–0.624	-1.18	0.179	0.238	0.302	0.0967	0.923
+ C3	0.599	0.441–0.752	0.901	0.188	0.368	-0.0264	-2.6	0.00932
+ C4	0.48	0.333–0.617	-1.247	0.184	0.213	0.263	0.0866	0.931
+ C5	0.527	0.365–0.686	3.066	0.219	0.00217	0.242	-0.25	0.802
+ C9	0.596	0.444–0.744	2.064	0.201	0.039	0.0439	-1.38	0.168
+ C1INH	0.715	0.567–0.843	1.73	0.185	0.0837	-0.0968	-3.45	0.000553
+ FH	0.621	0.476–0.769	1.068	0.188	0.286	-0.00639	-2.06	0.0392
+ FHR4	0.499	0.339–0.659	-0.84	0.177	0.401	0.0724	-0.197	0.844
+ FHR125	0.551	0.395–0.701	0.472	0.191	0.637	-0.0136	-2.54	0.0112
+ FI	0.515	0.358–0.666	0.669	0.177	0.503	0.0454	-0.665	0.506
+ clusterin	0.556	0.42–0.689	1.357	0.209	0.175	0.0493	-1.11	0.266
+ FD	0.639	0.503–0.776	2.329	0.256	0.0198	0.0117	-1.82	0.0693
+ properdin	0.624	0.468–0.761	3.153	0.323	0.00162	0.0239	-1.66	0.0968
+ FB	0.483	0.329–0.645	0.397	0.195	0.691	0.0784	0.226	0.821
+ sCR1	0.547	0.4–0.697	-0.692	0.169	0.489	0.0199	-1.44	0.149
+ C1s-C1INH	0.548	0.411–0.687	1.415	0.186	0.157	0.0751	-0.843	0.399
+ MASP1-C1INH	0.475	0.325–0.624	0.832	0.211	0.406	0.307	0.109	0.913
+ C5a	0.575	0.42–0.723	1.757	0.4	0.0789	0.022	-1.55	0.12

AUC, area under the curve; CI, 95% confidence interval (generated from 2000 bootstrap replicates); Z, Z score; SE, standard error. DeLong statistics were used to compare AUCs. TCC, terminal complement complex; C1INH, C1 inhibitor; FH, factor H; FHR4, FH-related protein 4; FHR125, FH-related proteins



1, 2, and 5; FI, factor I; FD, factor D; FB, factor B; sCR1, soluble complement receptor type 1; MASP1, mannose-associated serine protease 1.


## SUPPLEMENTARY FIGURE LEGENDS

**Supplementary Figure 1. Plasma concentrations of other complement proteins, anti-SARS-CoV-2 spike protein RBD antibody titers, and plasma haemolytic activity in healthy convalescent individuals and patients with long COVID. (A–D)** Dot plots showing plasma concentrations of FHR4 (A) and sCR1 (B), anti-SARS-CoV-2 spike protein RBD antibody titers (C), and plasma haemolytic activity (CH<sub>50</sub>) (D) in healthy convalescent individuals (*n* = 79) and patients with long COVID (*n* = 164–166). Horizontal bars represent mean values. Significance was assessed using an unpaired t-test.


**Supplementary Figure 2. Forest plot of regression coefficients (estimated values) from generalized linear models using complement protein concentrations in plasma to predict long COVID.** The direction and strength of effect for each complement protein is shown for healthy convalescent individuals and patients with long COVID. Proteins with positive coefficients are shown in red, and proteins that did not achieve significance are shown in grey. Error bars indicate the standard error for each regression coefficient. \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001.

**Supplementary Figure 3. Principal component analysis of complement analytes measured in this study. (A)** Variable correlation plot combining cosine<sup>2</sup> (cos<sup>2</sup>) scores showing the quality of representation for each principal component (PC). **(B)** Plot of individuals showing the quality of representation of each sample colored by clinical phenotype. Positively correlated variables cluster together, and negatively correlated variables are positioned on opposite sides of the plot origin (A, B). **(C)** Scree plot showing the percent contribution of variance for each PC. **(D, E)** Bar plots showing the percent contribution of each complement protein to PC1 (D) and PC2 (E).

# Supplementary Figure 1



Supplementary Figure 2



Supplementary Figure 3

